This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medical Products' Aug 5 Earnings Roster: BDX, RMD & More
by Trina Mukherjee
Let's see how Medical Product companies' stocks like BDX, RMD, CAH, ABMD and XRAY are poised ahead of their earnings releases.
Top Analyst Reports for Alphabet, Abbott & T-Mobile
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Abbott Laboratories (ABT), and T-Mobile US, Inc. (TMUS).
Medical Products' Aug 4 Earnings Roster: MCK, ABC & More
by Trina Mukherjee
The Medical Product companies' second-quarter results are likely to reflect robust earnings and revenue growth on solid base business recovery.
Medical Device Stocks' Earnings on Jul 28: TMO, ALGN & More
by Urmimala Biswas
The sector's Q2 results are likely to reflect solid earnings and revenue growth on strong base business recovery.
Abbott (ABT) Q2 Earnings Beat, Molecular Diagnostic Sales Drop
by Zacks Equity Research
Abbott's (ABT) Adult Nutrition sales benefit from improved sales performance of complete and balanced nutrition brand Ensure and diabetes nutrition brand, Glucerna in Q2.
Abbott (ABT) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 15.84% and 5.13%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
5 Hottest Earnings Charts This Week
by Tracey Ryniec
These companies have earnings surprise track records and charts to envy.
Lower COVID-19 Testing Demand to Drag Abbott (ABT) Q2 Earnings
by Zacks Equity Research
Apart from COVIG-19 test related hiccups, Abbott (ABT) is likely to have suffered from significant sales decline within its pediatric nutrition business in Q2.
Abbott (ABT) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $117.17, moving -1.25% from the previous trading session.
PAHC vs. ABT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PAHC vs. ABT: Which Stock Is the Better Value Option?
Grab these 3 MedTech Stocks That Outperformed S&P 500 YTD
by Trina Mukherjee
Snap up these three top stocks, WST, PAHC and RMD, which continue to show promise amid the pandemic and can turn out to be prudent investment choices.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $119.87 in the latest trading session, marking a +0.88% move from the prior day.
Abbott's (ABT) DAPT for High Bleeding Risk Gets FDA Approval
by Zacks Equity Research
Abbott's (ABT) DAPT can be discontinued safely early as short as 28 days with no higher risk in patient adverse events.
Child Health in Focus in Face of Delta Strain Threat: 3 Picks
by Urmimala Biswas
Here are three stocks, BAX, BRBR, and MRVI with a favorable Zacks Rank and huge prospects in child healthcare at present.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $115.93, moving -1.09% from the previous trading session.
Abbott (ABT) CE-Marked Panbio Test Now Widely Offered in Europe
by Zacks Equity Research
Abbott's (ABT) Panbio COVID-19 Antigen Self-Test is expected to facilitate mass screenings and aid in resumption of daily life activities with the gradual reopening of economies worldwide.
Abbott (ABT) Reports Late-Breaking Data on FreeStyle Libre
by Zacks Equity Research
Late-breaking data on Abbott's (ABT) FreeStyle Libre system demonstrates improvement in health and equity outcomes for diabetes patients.
Nutrien, Abbott, FedEx and NIKE highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Nutrien, Abbott, FedEx and NIKE highlighted as Zacks Bull and Bear of the Day
Diabetes Space Thrives on CGM Devices in 2021: 3 Stocks in Focus
by Debanjana Dey
CGM device stocks Medtronic (MDT), Dexcom (DXCM) and Tandem Diabetes (TNDM) are expected to continue their run over the next few months.
Bear of the Day: Abbott (ABT)
by Tracey Ryniec
Fewer COVID tests? Lower earnings.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $111.70, moving +0.78% from the previous trading session.
PAHC vs. ABT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PAHC vs. ABT: Which Stock Is the Better Value Option?
New Strong Sell Stocks for June 22nd
by Zacks Equity Research
ABT, BNL, ITRG, JAZZ, and MANU have been added to the Zacks Rank #5 (Strong Sell) List on June 22, 2021
Abbott's (ABT) Base Business Recovers, Lowered View Concerns
by Zacks Equity Research
According to Abbott (ABT), significant reductions in the number of COVID-19 cases in the United States and other major developed countries to hamper demand for COVID-19 testing in 2021.